TL;DR
Recent advances in AML research and vaccine development are examined, focusing on efforts to address highly aggressive and rare AML subtypes driven by aberrantly activated transcription factors and newly identified mutations and high-risk molecular markers that could enhance risk stratification for early disease progression.
AI-generated by Semantic Scholar
Authors
Daniel Ruben Akiola Sanya, Djamila Onésime
